Industrials29/100

Is RKLB-Rocket Lab USA, a buy?

Tuesday 11 August 2026

Why now: The stock is being repriced lower after very recent company updates and an earnings window, while the business continues to add meaningful government and future-Neutron backlog signals. This is a “fundamentals and program execution” story right now, not a momentum setup, so timing is about whether you believe Neutron and defense programs will convert into improving cash flow over the next 12–24 months.

Upside: Street targets imply about 43% upside versus the latest price snapshot in the fact pack, but that upside depends on hitting major milestones (especially Neutron schedule and margin improvement). A re-rating higher is plausible if cash burn narrows materially while backlog converts into revenue at higher gross margin.

Risks: Neutron schedule slips or early reliability issues could damage customer trust and delay the business model shift the valuation assumes. The other core risk is sustained negative free cash flow that forces more dilution even if revenue grows.